FDA approves Bayer's Kerendia to slow chronic kidney disease in type 1 diabetes
The label expansion extends the nonsteroidal MRA beyond type 2 diabetes to a broader CKD population.
Read at scanx.trade →Full coverage · 15 outlets
- scanx.trade · lead
- HCPLiveFDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
- Pharmaceutical ExecutiveFDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
- The American Journal of Managed CareFDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
- Fierce PharmaBayer’s Kerendia secures FDA nod as first drug in 30 years for Type 1 diabetes-associated kidney disease
- Drug TopicsFDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
- HealioFDA approves Kerendia for adults with CKD associated with type 1 diabetes
- Breakthrough T1DFinerenone Approved for Chronic Kidney Disease Associated With T1D
- European Pharmaceutical ReviewBayer’s Kerendia approved in US as first new CKD and type 1 diabetes therapy in three decades
- AllSciFDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney disease
- DealroomBayer's Kerendia wins FDA nod as first new treatment in 30 years for kidney disease in type 1 diabetes
- BayerFDA approves KERENDIA® as first new CKD treatment in 30 years for adults with type 1 diabetes
- Medical DialoguesFDA Approves Finerenone for CKD Associated With Type 1 Diabetes
- Indian Pharma PostBayer’s Kerendia wins FDA nod for chronic kidney disease linked to Type 1 diabetes
- BioSpaceBayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes